Overview
Introduction
Unmet need across the cancer market is high, with most therapies conferring low levels of
specificity and high toxicity. Development of cancer vaccines may be the holy grail, with the
promise of high specificity, low toxicity and prolonged activity. Despite years of R&D and
enhanced understanding of tumor immunology, a reproducible survival benefit has proved elusive,
leaving the market wide open.
Scope
- Examination of cancer vaccine pipeline with in-depth clinical and commercial profiles of Phase
III candidates, incorporating Datamonitor opinion
- Seven market sales forecasts, commercial potential and research/clinical/commercial assessment
of Phase III agents to 2014
- Analysis of the cancer vaccine market, identifying developmental, manufacturing, logistical,
regulatory and commercialization issues
- Insight and commentary from qualitative interviews with oncology opinion leaders in the US and
Europe
Report Highlights
Given the relative immaturity and lack of precedence of the cancer vaccine market, an entirely
new set of clinical and strategic issues has been brought to light. Significant hurdles need to be
overcome, both on a local and international level before successful commercialization of a cancer
vaccine can be realized.
Cancer vaccines will complement current treatment approaches, rather than serve as a replacement.
If the full potential of cancer vaccines is realized, the need for multiple-lines of treatment may
be eliminated, ultimately driving the cost of oncology care down.
The majority of the cancer vaccine pipeline constitutes off-the-shelf vaccines rather than
personalized or cell-based formulations. Although the former are capable of mass manufacture, the
latter have shown greater clinical benefit, but encompass a more complex and expensive formulation.
It is unclear which class will reach the market first.
Reasons to Purchase
- Identify the key cancer vaccines and cell therapies in the current pipeline based on sales
forecasts to 2014 and Datamonitor drug assessments
- Assess opportunities and risks for cancer vaccines and cell therapies within the oncology market
- Optimize development and commercialization of cancer vaccines by improving strategic planning
| 
View Cart
